about
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study.The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway.Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosisNovel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLEDelanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells
P921
Q33438839-9B90B08C-392E-4E2D-B9C0-15E84E4C4FD0Q38051475-8C62AB81-8878-4FD7-98E8-8B3EF375CBC3Q39294440-29AA89C3-0E52-4DD9-A975-60CEA303B50CQ40040623-C088BEB1-6F18-4F53-BF0E-858FF8DE24DCQ42875942-8AD3FCBF-62DC-43BC-A6A7-1207B28F0487Q43230776-C3ED73C4-7699-420D-8492-A92E52574C2CQ48522982-E5A234A2-6F64-4481-8FA2-E576CCE1E121Q64083300-427B8BFF-2177-46DC-82E5-DAF070B6D14CQ83006345-78E9774D-764A-4395-9F3A-DC237309FF4DQ88923648-B1B25B26-1BA8-4C3A-9028-08B51C77BB9B
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
delanzomib
@en
type
label
delanzomib
@en
altLabel
Delanzomib
@en
prefLabel
delanzomib
@en
P486
P592
P661
P662
P683
P2017
B([C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O
P2067
P231
847499-27-8
P233
B(C(CC(C)C)NC(=O)C(C(C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O
P234
1S/C21H28BN3O5/c1-13(2)12-18(2 ...... 8)(H,25,27)/t14-,18+,19+/m1/s1
P235
SJFBTAPEPRWNKH-CCKFTAQKSA-N
P274
C₂₁H₂₈BN₃O₅
P2868
P486
P592
CHEMBL270515
P652
6IF28942WO